We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Breath Test Developed to Diagnose Esophageal and Gastric Cancer

By LabMedica International staff writers
Posted on 05 Jul 2015
Print article
Image: A Selected-Ion Flow-Tube Mass Spectrometry Instrument for measuring chemical compounds in exhaled breath (Photo courtesy of Keele University).
Image: A Selected-Ion Flow-Tube Mass Spectrometry Instrument for measuring chemical compounds in exhaled breath (Photo courtesy of Keele University).
A breath test has been devised that can help doctors diagnose the early signs of esophageal and gastric cancer in minutes and the test can discriminate between malignant and benign esophageal cancer in patients for the first time.

Esophageal and gastric malignancies account for 15% of cancer-related deaths globally and both cancers are usually diagnosed in the advanced stages because they rarely cause any noticeable symptoms when they first develop. As a result, the long-term survival rate is 13% for esophageal cancer and 15% for gastric cancer in the UK.

A team of scientists led by those at Imperial College London (UK) analyzed breath samples of 210 with esophageal and gastric cancer patients using the breath test from 2011 to 2013. Patients who are at risk of developing these cancers and those who had benign tumors were also tested. To take the test, patients breathe into a device similar to a breathalyzer which is connected to a bag. The compounds in their exhaled breath are analyzed by a selected ion flow tube mass spectrometer.

The test looks for chemical compounds in exhaled breath that are unique to patients with esophageal and gastric cancer. The cancers produce a distinctive smell of volatile organic compounds (VOC), chemicals that contain carbon and are found in all living things, which can help doctors detect early signs of the disease. The team was able to identify for the first time the number of VOCs in breath samples by using a Profile-3 Selected Ion Flow Tube Mass Spectrometry instrument, an analytical apparatus used to identify what chemicals are present in a sample.

Twelve VOCs: pentanoic acid, hexanoic acid, phenol, methyl phenol, ethyl phenol, butanal, pentanal, hexanal, heptanal, octanal, nonanal, and decanal were present at significantly higher concentrations in the cancer groups than in the non-cancer controls This quantitative technology identified VOCs that were present at significantly higher concentrations in patients with esophageal and gastric cancer than in non-cancerous patients. The scientists say that the results could be used to set a biomarker, a biological feature used to measure the presence or progress of a disease.

George B. Hanna, FRCS, PhD, the lead author of the study said, “Esophageal and gastric cancers are on the rise in the UK with more than 16,000 new cases diagnosed each year. The current method for detecting these cancers is expensive, invasive and a diagnosis is usually made at a late stage and often the cancer has metastasized. This makes it harder to treat and results in poor long-term survival rates. Our breath test could address these problems because it can help diagnose patients with early nonspecific symptoms as well as reduce the number of invasive endoscopies carried out on patients, which often lead to negative results. Diagnosis at an early stage could give patients more treatment options and ultimately save more lives.” The study was published on June 25, 2015, in the journal Annals of Surgery.

Related Links:

Imperial College London 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.